Expressions of ANP32B and RAB10 in bone marrow of pediatric patients with acute myeloid leukemia and their relationship with clinical characteristics and survival prognosis

HE Minhui; YANG Chao; ZHANG Xiaodong; ZHANG Xianhui

doi:10.3969/j.issn.1674-3806.2025.08.10

Abstract：Objective To analyze the expressions of acidic leucine-rich nuclear phosphoprotein 32 family member B(ANP32B)and RAS oncogene family member 10(RAB10)in bone marrow of pediatric patients with acute myeloid leukemia(AML)and their relationship with clinical characteristics and survival prognosis.Methods A total of 96 pediatric patients with AML who were admitted to Shanxi Children's Hospital from March 2019 to March 2021 were recruited as AML group.Other 50 children who underwent bone marrow puncture for the examination of other diseases during the same period and were excluded from malignant hematological diseases were selected as control group.The levels of ANP32B and RAB10 in bone marrow were detected by using quantitative polymerase chain reaction(qPCR).The therapeutic effect was evaluated after the end of the first course of treatment.The survival prognosis of the pediatric patients with AML during the 3-year follow-up period was recorded.Cox regression was used to analyze the influencing factors of survival prognosis in the pediatric patients with AML.Results The ANP32B level in the AML group was significantly higher than that in the control group[(3.12±0.43)vs(1.05±0.22),t=31.898,P＜0.001],and the RAB1 0 level in the AML group was significantly higher than that in the control group[(2.85±0.37)vs(0.95±0.21),t=33.569,P＜0.001].The levels of ANP32B and RAB10 in the pediatric patients with AML who did not achieve complete remission in the first course of treatment and were stratified as high risk were significantly increased(P＜0.05).The follow-up time of the pediatric patients was 4-36(28.21±4.16)months,and their 3-year overall survival rate was 66.67％.The survival prognosis of the ANP32B low-expression group(≤3.12,50 cases)was significantly better than that of the ANP32B high-expression group(＞3.12,46 cases)(log-rank test:x2=9.420,P=0.001).The survival prognosis of the RAB10 low-expression group(≤2.85,49 cases)was significantly better than that of the RAB10 high-expression group(＞2.85,47 cases)(log-rank test:x2=19.720,P＜0.001).The survival prognosis of the ANP32B+RAB10 low co-expression group was significantly better than that of the ANP32B+RAB10 high co-expression group(log-rank test:x2=56.590,P＜0.001).The results of multivariate Cox regression analysis showed that risk stratification as high risk,non-complete remission in the first course of treatment,high expression of ANP32B,and high expression of RAB10 were independent risk factors for death in the pediatric patients with AML(P＜0.05).Conclusion The levels of ANP32B and RAB10 in the bone marrow of pediatric patients with AML are elevated,and the levels are related to risk stratification,whether there is complete remission in the first course of treatment,and survival prognosis.